PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and.
Verona Pharma To Present Additional Analyses Of Positive Phase 3 ENHANCE Studies In COPD At ATS 2024 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Among adults 40 years and older with chronic obstructive pulmonary disease (COPD), there is a higher prevalence of cardiovascular diseases (CVDs) compared with a general population without COPD.
Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Verona Pharma plc (VRNA) Reports Publication of Phase 3 ENHANCE Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.